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Summary
Diffuse myocardial fibrosis in hypertensive left ventricu-
lar hypertrophy (LVH) is not readily detected by con-
ventional late gadolinium enhanced CMR. Our study
was aimed to detect diffuse myocardial fibrosis in these
patients as compared to age matched normal controls,
using a T1 mapping technique. Fibrosis was quantified
by calculating the partition coefficient (l) and volume of
distribution (Vd) of gadolinium (Gd) following a bolus
injection of Gd. We observed that the values for l and
Vd were higher in LVH than controls. A positive asso-
ciation was also noted between LV mass and l.
Background
Diffuse myocardial fibrosis can occur in hypertensive left
ventricular hypertrophy (LVH) and is not readily
detected by conventional late gadolinium enhanced
CMR. We previously described a shortened Modified
Look-Locker Inversion Recovery (3-5 MOLLI) T1-map-
ping technique which can quantify fibrosis by calculating
the partition coefficient (l) and volume of distribution
(Vd) of gadolinium (Gd) following a bolus injection of
Gd.[1] We hypothesized that this technique could detect
fibrosis in subjects with hypertensive LVH and normal
ejection fraction. This could have important implications
for assessment of diastolic heart failure and to monitor
benefits of anti-fibrotic, anti-hypertensive therapy. We
aimed to detect diffuse myocardial fibrosis in hyperten-
sive patients with LVH as compared to age matched
normal controls.
Methods
T1 mapping was performed in 11 subjects with hyper-
tensive LVH (53±16 years) and normal ejection fraction,
and 7 age-matched healthy volunteers (50±10 years) on
a Siemens 1.5T Avanto using 3-5 MOLLI (11 heart
beats, 2 inversions, 3 recovery beats, 8 images). Patients
with known coronary disease, significant valvular dis-
ease, and other causes of LVH were excluded. LV mass
and function was assessed by SSFP cine imaging.
MOLLI sequence parameters included: TE/TR/FA 1.1
ms/2.5ms/35°, FOV= 340 x 260, resolution 1.8mm x
1.8mm, thickness 8mm. T1 was determined pre-contrast
and 10,15 and 20 minutes following injection of 0.15
mmol/kg Gd-DTPA. Hematocrit (Hct) was measured in
all subjects. T1 maps were calculated and manually seg-
mented using an in-house MATLAB program. l was
determined from the slope of a plot of 1/T1 of the myo-
cardium versus 1/T1 of the blood. Vd was calculated as
(1-Hct)*l. Values were compared between groups using
2-tailed unpaired t-tests.
Results
The LVH group had significantly higher blood pressure
and LV mass than age-matched controls (Table). Heart
rate, Hct and creatinine were similar between groups.
Values for l and Vd were higher in LVH (0.49±0.04 and
0.31±0.02) than controls (0.44±0.01 and 0.27±0.01)
(p=0.003 and 0.004) respectively (Figure). There was a
positive association between LV mass and l (Spearman
rho=0.66; p=0.01).
Conclusions
Determination of l a n dV db yT 1m a p p i n ga f t e rG d
bolus with a reduced breath-hold 3-5 MOLLI pulse
sequence is a robust method capable of quantifying dif-
fuse myocardial fibrosis in hypertensive patients with
LVH and normal ejection fraction. l correlates with LV
mass. These findings support the application of T1
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and reduce fibrosis in hypertensive heart disease.
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Table 1 Baseline characteristics of hypertensive LVH subjects and controls
Hypertensive LVH (n=11) Age matched controls (n=7) P value
Sex 7 females; 4 males 6 females; 1 male
Age (yrs) 53±16 50±10 0.63
Systolic BP (mm Hg) 151±15 120±20 0.002
Diastolic BP (mm Hg) 82±13 62±9 0.002
LV Mass (g) 165±46 91±21 0.001
Ejection fraction (%) 64±7 61±5 0.33
Heart Rate (beats/min) 75±15 68±9 0.28
Hematocrit (%) 37.8±4.0 38.0±2.9 0.94
Creatinine (mg/dL) 0.96±0.28 0.73±0.08 0.06
eGFR 79±16 72±15 0.50
Figure 1 Partition coefficient and volume of distribution of Gadolinium for subjects with hypertensive LVH versus healthy age matched controls
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